reddit medvi tirzepatide TheDoseReport Announces Which GLP-1 is Best? Semaglutide and Stopping Tirzepatide: What To Expect

It is essential to disclose all medications, including any GLP-1 agonists, as these may influence symptom assessment and disease monitoring

A morning injection creates a visible routine cuesimilar to taking a daily vitaminthat builds accountability and reduces the likelihood of forgetting your weekly dose

Switching studies provide partial insight Several studies have examined one-directional switching, primarily from semaglutide to tirzepatide

Receptor-target and efficacy comparison: GLP-1 class agents | Agent | GLP-1 | GIP | Glucagon | Approval | Best trial weight loss | |---|---|---|---|---|---| | Liraglutide (Saxenda) | Yes | No | No | FDA-approved | 8.0% at 56 weeks (SCALE) | | Dulaglutide (Trulicity) | Yes | No | No | T2D only | 3.0 kg mean at 52 weeks | | Semaglutide (Wegovy) | Yes | No | No | FDA-approved | 14.9% at 68 weeks (STEP-1) | | Tirzepatide (Zepbound) | Yes | Yes | No | FDA-approved | 20.9% at 72 weeks (SURMOUNT-1) | | Retatrutide | Yes | Yes | Yes | Investigational | 24.2% at 48 weeks (Phase 2) | Liraglutide and Dulaglutide: Where They Fit Now Liraglutide (Saxenda, 3 mg once daily subcutaneous) was the first GLP-1 agonist approved specifically for obesity in the United States

In its third-quarter results update this week, Novo Nordisk also revealed it has now filed for approval of oral semaglutide in the EU for launch in "selected markets," and sees the drug as "a big step forward in terms of expanding the market and for those individuals that align better with taking a pill for their obesity." Both companies have been investing heavily in direct-to-consumer (DTC) sales channels for cash purchasing of their current injectable products, and Novo Nordisk said on the call it will make oral semaglutide available across all its sales channels if approved.

By modulating this pathway, BPC-157 may contribute to improved vascular response and tissue resilience